Correlation Between Affimed NV and AN2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Affimed NV and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Affimed NV and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Affimed NV and AN2 Therapeutics, you can compare the effects of market volatilities on Affimed NV and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Affimed NV with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Affimed NV and AN2 Therapeutics.
Diversification Opportunities for Affimed NV and AN2 Therapeutics
-0.43 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Affimed and AN2 is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Affimed NV and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Affimed NV is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Affimed NV are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Affimed NV i.e., Affimed NV and AN2 Therapeutics go up and down completely randomly.
Pair Corralation between Affimed NV and AN2 Therapeutics
Given the investment horizon of 90 days Affimed NV is expected to under-perform the AN2 Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Affimed NV is 1.12 times less risky than AN2 Therapeutics. The stock trades about -0.11 of its potential returns per unit of risk. The AN2 Therapeutics is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest 110.00 in AN2 Therapeutics on September 3, 2024 and sell it today you would earn a total of 57.00 from holding AN2 Therapeutics or generate 51.82% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Affimed NV vs. AN2 Therapeutics
Performance |
Timeline |
Affimed NV |
AN2 Therapeutics |
Affimed NV and AN2 Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Affimed NV and AN2 Therapeutics
The main advantage of trading using opposite Affimed NV and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Affimed NV position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.Affimed NV vs. DiaMedica Therapeutics | Affimed NV vs. Lyra Therapeutics | Affimed NV vs. Centessa Pharmaceuticals PLC |
AN2 Therapeutics vs. DiaMedica Therapeutics | AN2 Therapeutics vs. Lyra Therapeutics | AN2 Therapeutics vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |